Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial

NCT05635591 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT05635591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05635591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial
Lead sponsor
Tongji Hospital
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
January 16, 2023
Completion date
December 31, 2026
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ebv-associated haematologic neoplasms